NIH Begins Human Testing of Investigational Zika Vaccine
Posted at 2:15 p.m.
The National Institutes of Health (NIH) reports today that the National Institute of Allergy and Infectious Diseases (NIAID) has launched a clinical trial of a vaccine candidate intended to prevent Zika virus infection.
The early-stage study will evaluate the experimental vaccine’s safety and ability to generate an immune system response in participants. At least 80 healthy volunteers ages 18-35 years at three study sites in the United States, including the NIH Clinical Center in Bethesda, Md., are expected to participate in the trial.
Scientists at NIAID’s Vaccine Research Center (VRC) developed the investigational vaccine — called the NIAID Zika virus investigational DNA vaccine — earlier this year.
Read more in this NIH news release. Learn more about Zika from the county’s Health Department, including flyers and posters you can print out and share, public service announcements and other resources.